# Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies

> **NCT07098299** · PHASE1 · RECRUITING · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT07098299
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-18
- **Primary completion:** 2027-07-07
- **Final completion:** 2028-07-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07098299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07098299, "Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07098299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*